SS-31 (Elamipretide)

SS-31 research context

SS-31 is an aromatic-cationic tetrapeptide developed to target mitochondria without requiring a highly negative mitochondrial membrane potential for uptake. It is studied primarily for its localisation to the inner mitochondrial membrane and its interaction with cardiolipin. This distinguishes SS-31 from conventional antioxidants that may act more diffusely within cells.

The contemporary scientific model of SS-31 activity extends beyond direct free-radical scavenging. Research now focuses on cardiolipin-dependent membrane organisation, electron-transport efficiency, respiratory supercomplex function, cristae integrity, protein-lipid interactions and regulation of mitochondrial redox balance. However, its complete mechanism has not been resolved, and different experimental findings may reflect multiple interacting effects rather than a single molecular target. This section summarises findings from scientific publications and regulatory sources for educational and laboratory-research purposes.

Current areas of scientific investigation

Active SS-31 research spans several overlapping fields, each examining a different aspect of mitochondrial structure, energetics and physiology:

• Cardiolipin and inner mitochondrial membrane biology. Cardiolipin is a specialised phospholipid concentrated in the inner mitochondrial membrane that supports cristae organisation and interacts with many oxidative-phosphorylation proteins. SS-31 research examines how peptide binding affects cardiolipin packing, surface charge, membrane organisation and the stability of mitochondrial protein complexes, with biophysical studies indicating that SS-31 can alter membrane electrostatics and lipid organisation without destabilising lamellar membranes.
• Mitochondrial bioenergetics. Researchers investigate SS-31 in models of impaired oxidative phosphorylation, abnormal proton leak, reduced ATP-generating capacity and inefficient electron transport, assessing oxygen consumption, respiratory control, membrane potential, ATP production and electron leakage. Reported improvements in dysfunctional experimental systems should be interpreted as model-specific rather than universal effects on all mitochondria.
• Oxidative stress and redox biology. Mitochondrial electron leakage can contribute to reactive oxygen species formation, and SS-31 has been examined for its influence on mitochondrial redox balance, protein oxidation, lipid oxidation and antioxidant-response pathways. Its activity is increasingly understood as potentially arising from improved electron-transport organisation and cardiolipin protection rather than only direct antioxidant scavenging.
• Mitochondrial protein interactions. Proteomic and biochemical studies have identified a range of potential SS-31-interacting mitochondrial proteins, including those associated with respiratory complexes, membrane transport and energy metabolism, and direct interaction with the adenine nucleotide translocator has been reported in ageing skeletal-tissue research. Further work is required to determine which interactions are primary drivers of biological effects and which are secondary consequences of altered membrane organisation.
• Skeletal-tissue and exercise physiology. SS-31 has been investigated in skeletal-tissue models involving mitochondrial dysfunction, ageing, exercise capacity and altered ADP sensitivity, with preclinical studies reporting improvements in exercise tolerance and mitochondrial physiology in aged animals. Human trial results have been mixed, and the Phase 3 MMPOWER-3 study in primary mitochondrial myopathy did not meet its primary walking-distance or fatigue endpoints at 24 weeks.
• Cardiac and vascular research. Experimental studies have examined SS-31 in cardiac ageing, heart-failure models, ischaemia-reperfusion injury and vascular dysfunction; in aged mice, exposure was associated with improvements in diastolic function, mitochondrial proton leak and cardiac redox balance. These findings are important for mechanistic research but do not establish an approved cardiovascular indication.
• Renal research. SS-31 has been investigated in experimental kidney disease, including models of acute injury, chronic dysfunction, mitochondrial depolarisation and oxidative stress; the renal literature remains predominantly preclinical, and published reviews emphasise that underlying mechanisms require further clarification.
• Neurological and neurodegeneration research. Laboratory studies have explored mitochondrial dysfunction in neural cells, neural stress responses, oxidative injury and age-associated neurological models; these investigations remain experimental, and no neurological indication has been approved for elamipretide.
• Ophthalmic research. Elamipretide has been evaluated in ophthalmic development programmes, including studies involving age-related macular degeneration; a Phase 3 study is evaluating activity, safety and pharmacokinetics in dry age-related macular degeneration, with completion expected after 2026, and no ophthalmic approval has been established at the time of writing.
• Barth syndrome and regulatory development. Barth syndrome is a rare mitochondrial disorder associated with abnormalities in cardiolipin metabolism. In September 2025, the U.S. FDA granted accelerated approval to Forzinity, the prescription elamipretide formulation, for a defined indication in adult and paediatric patients with Barth syndrome weighing at least 30 kilograms, based on an intermediate endpoint and subject to confirmation in further trials. This regulatory status must not be generalised to non-prescription research products: the approved drug has defined manufacturing controls, formulation, labelling and prescribing requirements that are distinct from laboratory-grade SS-31 supplied by research vendors.

Current evidence landscape

SS-31 has a more advanced evidence base than many experimental peptides because it has undergone preclinical investigation, multiple controlled human trials and regulatory review. Nevertheless, evidence differs substantially by indication.

For primary mitochondrial myopathy, early findings were encouraging, but the larger MMPOWER-3 study did not separate from placebo for the principal walking and fatigue measures at 24 weeks. Post-hoc analyses have explored whether genetically defined subgroups may respond differently, but such analyses are exploratory and require prospective confirmation.

For Barth syndrome, the FDA has granted accelerated approval for a specific prescription formulation and population. For other proposed applications, including ageing, renal disorders, heart failure, neurological disease and most metabolic uses, SS-31 remains investigational. The evidence should therefore be described according to indication rather than characterised broadly as either proven or unproven.

Scientific limitations

• Many mechanistic findings derive from cells and animal models.
• The precise hierarchy of cardiolipin, membrane and protein interactions remains unresolved.
• Human trial findings have varied by disease, endpoint and study design.
• Positive preclinical results have not consistently translated into successful study endpoints.
• Exploratory subgroup analyses require prospective validation.
• The FDA approval applies only to Forzinity for a defined Barth syndrome indication.
• Product quality and equivalence cannot be inferred across different SS-31 suppliers or formulations.
• The livvmore research product must not be presented as equivalent to the approved prescription drug.

Selected scientific references

• Mitchell W, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics and lipid packing. 2020.
• Chavez JD, et al. Mitochondrial protein interaction landscape of SS-31. 2020.
• Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018.
• Karaa A, et al. Neurology. 2023.
• Chiao YA, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. 2020.
• Campbell M, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. 2019.
• Pharaoh G, et al. 2023.
• U.S. FDA. Accelerated approval announcement, Barth syndrome. September 19, 2025.
• U.S. FDA. Forzinity prescribing information. Initial U.S. approval 2025.

For laboratory research use only. Not for human or veterinary use.